根據該協議，Neurocrine獲授予在大中華區以外開發、製造及商業化藥捷安康 NLRP3藥物平台中的NLRP3抑製劑的獨家權利，本公司擁有在大中華區（內地、 香港、台灣、澳門）開發、製造及商業化NLRP3抑制劑的權利。根據該協議，公 司將有權獲得預付款，並且根據Neurocrine的開發和商業化進展，公司可能會收 到與研發里程碑和銷售里程碑相關的進一步里程碑付款，該協議的總潛在價值為 8.815億美元。該協議進一步涵蓋訂約方之間的研究合作，以進一步發展NLRP3相 關技術。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 TransThera Sciences (Nanjing), Inc. 藥捷安康（南京）科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2617） 自願性公告 與Neurocrine達成項目合作 本公告由藥捷安康（南京）科技股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東 ...

Core Viewpoint - The innovative drug concept stocks experienced a significant rise on October 31, with multiple companies reaching notable gains in their stock prices [1]. Group 1: Stock Performance - Sangfor Health (三生国健) saw a 20% increase, reaching a price of 72.96 [2] - Shuyou Pharmaceutical (舒泰神) rose by 14.29%, with a current price of 36.47 [2] - TuoJing Life (透景生命) increased by 11.97%, priced at 24.78 [2] - Maiwei Biotechnology (迈威生物-U) gained 11.69%, now at 47.23 [2] - Zejing Pharmaceutical (泽璟制药-U) rose by 11.06%, with a price of 99.18 [2] - Rongchang Biotechnology (荣昌生物) increased by 10.87%, priced at 98.30 [2] - Other notable increases include Hite Biotechnology (海特生物) at 10.33% and Weili Chemical (微粒化工艺物) at 10.19% [2]. Group 2: Hong Kong Market Performance - In the Hong Kong market, Fosen Pharmaceutical (福森药业) surged by 53.62%, reaching a price of 1.060 [3] - Yingtu Biotechnology (映图生物-B) increased by 12.44%, priced at 318.200 [3] - Yaojie Ankang (药捷安康-B) rose by 9.45%, with a current price of 190.000 [3] - Other companies such as Xinda Biopharmaceutical (信达牛物) and Jinfang Pharmaceutical (劲方医药) also saw increases of 8.18% and 8.05%, respectively [3].

Core Viewpoint - The innovative drug concept stocks experienced a significant rally on October 31, with multiple stocks reaching their daily limit up or showing substantial gains, indicating a strong market sentiment towards the pharmaceutical sector [1]. Group 1: Stock Performance - Sangfor Health (三生国健) surged by 20% to a price of 72.96 [2] - Shuyou Shen (舒泰神) increased by 14.29% to 36.47 [2] - Tuo Jing Life (透景生命) rose by 11.97% to 24.78 [2] - Maiwei Biotechnology (迈威生物-U) gained 11.69% to 47.23 [2] - Zejing Pharmaceutical (泽璟制药-U) climbed 11.06% to 99.18 [2] - Rongchang Biopharmaceutical (荣昌生物) went up by 10.87% to 98.30 [2] - Other notable gainers included Haitai Biotechnology (海特生物) at +10.33% and Weiguan Biotechnology (微感生物) at +10.19% [2]. Group 2: Hong Kong Market Performance - Fosen Pharmaceutical (福森药业) saw a remarkable increase of 53.62% to 1.060 [3] - Yingtou Biotechnology (映图生物-B) rose by 12.44% to 318.200 [3] - Yaojie Jiankang (药捷家康-B) increased by 9.45% to 190.000 [3] - Other stocks such as Innovent Biologics (信达生物) and Jinfang Pharmaceutical (劲方医药) also experienced gains of 8.18% and 8.05% respectively [3].

Core Viewpoint - On October 22, the Hang Seng Index fell by 0.94% to close at 25,781.77 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 10.018 billion [1] Group 1: Market Activity - The total trading volume for the Stock Connect on October 22 was HKD 106.582 billion, with a net purchase of HKD 10.018 billion [1] - The Shanghai Stock Connect accounted for HKD 66.693 billion in trading volume, with a net purchase of HKD 6.693 billion, while the Shenzhen Stock Connect had a trading volume of HKD 39.887 billion and a net purchase of HKD 3.325 billion [1] Group 2: Active Stocks - In the Shanghai Stock Connect, Alibaba-W had the highest trading volume at HKD 41.14 billion, followed by SMIC and Innovent Biologics with HKD 34.07 billion and HKD 32.39 billion respectively [1] - The top net purchase stock was the Tracker Fund of Hong Kong (盈富基金) with a net purchase of HKD 12.93 billion, despite a closing price drop of 1.05% [1] - Alibaba-W recorded the highest net sell amount at HKD 1.80 billion, closing down by 1.94% [1] Group 3: Shenzhen Stock Connect Activity - In the Shenzhen Stock Connect, Innovent Biologics led with a trading volume of HKD 26.84 billion, followed by Alibaba-W and Pop Mart with HKD 24.66 billion and HKD 23.36 billion respectively [2] - The Tracker Fund of Hong Kong (盈富基金) also had a net purchase of HKD 7.02 billion, closing down by 1.05% [2] - Innovent Biologics had the highest net sell amount at HKD 2.53 billion, with a closing price drop of 1.96% [2]

Core Insights - On October 22, 2025, Alibaba-W (09988), SMIC (00981), and Innovent Biologics (01801) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 4.114 billion, 3.407 billion, and 3.239 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Innovent Biologics (01801), Alibaba-W (09988), and Pop Mart (09992) led the trading volume, with amounts of 2.684 billion, 2.466 billion, and 2.336 billion respectively [1] Southbound Stock Connect (Hong Kong-Shanghai) - Top three active stocks by trading amount: - Alibaba-W (09988): 4.114 billion, net buy of -0.18 billion - SMIC (00981): 3.407 billion, net buy of 0.292 billion - Innovent Biologics (01801): 3.239 billion, net buy of 0.374 billion [2] - Other notable stocks include: - Pop Mart (09992): 2.730 billion, net buy of 0.199 billion - Tencent Holdings (00700): 1.716 billion, net buy of 0.259 billion [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Top three active stocks by trading amount: - Innovent Biologics (01801): 2.684 billion, net buy of -0.253 billion - Alibaba-W (09988): 2.466 billion, net buy of 0.172 billion - Pop Mart (09992): 2.336 billion, net buy of 0.041 billion [2] - Other notable stocks include: - SMIC (00981): 1.857 billion, net buy of 0.350 billion - Tencent Holdings (00700): 1.081 billion, net buy of 0.049 billion [2]

Core Viewpoint - Some Hong Kong pharmaceutical stocks have shown strong performance, with notable increases in share prices for specific companies [1] Group 1: Stock Performance - Yaojie Ankang-B (02617.HK) experienced a significant increase, rising over 25% at one point and closing up 14.13% [1] - Shenghe Biotechnology-B (02898.HK) saw a rise of 4.31% [1] - Beikang Medical-B (02170.HK) increased by 3.65% [1]

Core Viewpoint - The stock of Zai Lab Limited (药捷安康-B) surged over 25% following the announcement of new research data on its core product, Tiengogatinib, for cholangiocarcinoma at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] Company Summary - Zai Lab's Tiengogatinib is an innovative multi-target small molecule kinase inhibitor developed in-house, currently in the registration clinical phase [1] - The drug targets tumor cells and improves the tumor microenvironment to exert anti-tumor effects [1] - Tiengogatinib is undergoing multiple clinical trials for cholangiocarcinoma, prostate cancer, and breast cancer in both the US and China [1] Regulatory Approvals - Tiengogatinib has received several designations, including Orphan Drug Designation (ODD) and Fast Track Designation from the US FDA for cholangiocarcinoma and prostate cancer [1] - The drug is also included in the breakthrough therapy list approved by China's NMPA and has received ODD from the European EMA for cholangiocarcinoma [1]

Group 1 - The core point of the article highlights that the stock of the company药捷安康-B experienced a significant increase, rising over 25% during the trading session on October 22 [1] Group 2 - The article notes that the stock's performance indicates strong market interest and potential investor confidence in the company [1]

Core Viewpoint - The stock of药捷安康-B (02617) experienced a significant decline, dropping over 11% during trading, with a current decrease of 9.74% to HKD 176.2, and a trading volume of HKD 591 million. The company announced plans to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, representing approximately 11.33% of the total issued shares, pending regulatory approvals [1][1][1]. Group 1 - The company’s stock price fell sharply, with a notable drop of over 11% during trading hours [1] - As of the latest update, the stock is down 9.74%, trading at HKD 176.2, with a total transaction volume of HKD 591 million [1] - The board has approved an application to the China Securities Regulatory Commission for the conversion of domestic shares into H-shares, which will be eligible for listing and trading on the main board of the Hong Kong Stock Exchange [1][1][1] Group 2 - The stock had a strong rebound from October 16 to 17, with a cumulative increase of nearly 80% over two days [1] - The rebound was characterized as a violent surge driven by international short-term speculative funds, which were utilized by domestic major funds as an "exit window" [1] - The largest holding group did not participate in the buying but instead became the largest seller, indicating that the foundation of this rebound was weakened and reliant on subsequent speculative inflows [1][1][1]

Core Viewpoint - The stock of药捷安康-B (02617.HK) experienced a significant decline, dropping over 11% during trading, with a current decrease of 9.74%, priced at 176.2 HKD, and a trading volume of 5.91 million HKD [2] Company Summary -药捷安康-B's stock price fell to 176.2 HKD, reflecting a notable decline in market performance [2] - The trading volume reached 5.91 million HKD, indicating active trading despite the price drop [2]